DepoCyt
Showing 26 - 50 of 74
Leukemia Trial in Houston (LY2510924, Idarubicin, Cytarabine)
Completed
- Leukemia
- LY2510924
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Nov 14, 2019
Glioblastoma Multiforme, Glioma, Astrocytoma Trial in Charleston (ITV DepoCyt + Temozolomide)
Terminated
- Glioblastoma Multiforme
- +3 more
- ITV DepoCyt + Temozolomide
-
Charleston, South CarolinaMedical University of South Carolina
Jan 25, 2019
Leukemia Trial in Houston (Decitabine, Idarubicin, Cytarabine)
Completed
- Leukemia
- Decitabine
- +3 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
May 28, 2019
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma Trial in Valhalla, Charlotte (Clofarabine,
Active, not recruiting
- Acute Lymphoblastic Leukemia
- +4 more
-
Valhalla, New York
- +1 more
Oct 29, 2021
Leukemia Trial in Houston (drug, radiation, biological)
Active, not recruiting
- Leukemia
- Busulfan
- +11 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
May 22, 2019
Leukemia, Acute Lymphocytic Leukemia Trial in Houston (Everolimus (RAD001), Cyclophosphamide, Vincristine)
Completed
- Leukemia
- Acute Lymphocytic Leukemia
- Everolimus (RAD001)
- +9 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 5, 2019
Acute Lymphoblastic Leukemia Trial in Spain (vINCRISTINE, Dexamethasone, Methotrexate)
Recruiting
- Acute Lymphoblastic Leukemia
- vINCRISTINE
- +3 more
-
Palma de Mallorca, Baleares, Spain
- +74 more
Jan 17, 2022
Acute Myeloid Leukemia Trial in Gainesville (Midostaurin, Cytarabine)
Withdrawn
- Acute Myeloid Leukemia
-
Gainesville, FloridaUniversity of Florida
Oct 18, 2018
Acute Myeloid Leukemia Trial in Houston (Clofarabine, Idarubicin, Cytarabine)
Completed
- Acute Myeloid Leukemia
- Clofarabine
- +2 more
-
Houston, TexasUT MD Anderson Cancer Center
Sep 10, 2018
Leukemia Trial in Houston (E7070, Idarubicin, Cytarabine)
Completed
- Leukemia
- E7070
- +3 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jun 4, 2018
Leukemia, Myeloproliferative Diseases Trial in Houston (Clofarabine, Cytarabine)
Completed
- Leukemia
- Myeloproliferative Diseases
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jun 5, 2018
Burkitt's Lymphoma, Burkitt'S-like Lymphoma Trial in Houston (Rituximab, Cyclophosphamide, Doxorubicin)
Completed
- Burkitt's Lymphoma
- Burkitt'S-like Lymphoma
- Rituximab
- +7 more
-
Houston, TexasThe University of Texas M. D. Anderson Cancer Center
Apr 18, 2018
Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Houston (Cytarabine, Daunorubicin,
Terminated
- Leukemia
- +3 more
- Cytarabine
- +12 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
May 9, 2018
Acute Myeloid Leukemia Trial in Iowa City (Cytarabine, Lovastatin)
Terminated
- Acute Myeloid Leukemia
-
Iowa City, IowaHolden Comprehensive Cancer Center
Dec 5, 2017
Adult T-cell Leukemia-Lymphoma Trial in Worldwide (KW-0761, Pralatrexate, gemcitabine plus oxaliplatin)
Completed
- Adult T-cell Leukemia-Lymphoma
- KW-0761
- +3 more
-
Los Angeles, California
- +19 more
Aug 21, 2018
Acute Myeloid Leukemia Trial in Porto Alegre (NK Cells + Chemotherapy Starting)
Unknown status
- Acute Myeloid Leukemia
- NK Cells + Chemotherapy Starting
-
Porto Alegre, Rio Grande Do Sul, BrazilCentro Terapia e Tecnologia Celular
Oct 11, 2019
CNS Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer Trial in Seattle (methotrexate, liposomal cytarabine,
Completed
- Central Nervous System Metastases
- +4 more
- methotrexate
- +3 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center/University of Washington
Jun 7, 2017
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma Trial in Detroit (biological, drug, radiation)
Completed
- Chronic Myeloproliferative Disorders
- +5 more
- rituximab
- +9 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
May 26, 2017
Leukemia Trial in Houston (Omacetaxine, Cytarabine)
Completed
- Leukemia
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Apr 30, 2018